Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA) announced that on April 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to six new employees totaling 153,750 shares under the 2023 Inducement Option Plan, as amended.
Kura Oncology (Nasdaq: KURA) announced that on April 1, 2026 its Compensation Committee granted inducement nonstatutory stock options to six new employees totaling 153,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an $8.34 exercise price (April 1, 2026 closing price) and vests over four years: 25% at one year, then monthly over 36 months, subject to continued service and plan terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement details routine inducement equity grants: nonstatutory options for 153,750 shares ...
Analysis
This announcement details routine inducement equity grants: nonstatutory options for 153,750 shares to six new employees at an exercise price of $8.34, vesting over four years. Similar grants on Feb 6 and Mar 6 reflected ongoing hiring as Kura scales commercial and pipeline activities. Investors may watch cumulative equity-based compensation, upcoming clinical milestones, and commercialization updates to gauge how added talent supports long-term execution.
Key Figures
Inducement option shares:153,750 sharesNew employees:6 employeesExercise price:$8.34 per share+3 more
Inducement option shares
153,750 shares
Nonstatutory stock options granted to new employees on April 1, 2026
New employees
6 employees
Recipients of inducement option grants under 2023 Inducement Option Plan
Exercise price
$8.34 per share
Closing price of KURA common stock on April 1, 2026
Vesting period
4 years
Total vesting term for inducement stock options
Initial cliff vesting
25% of shares
Vest on one-year anniversary of vesting commencement date
Remainder vesting
36 months
Monthly vesting of remaining shares after initial one-year cliff
"approved the stock options as an inducement material... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement awardsfinancial
"the Compensation Committee... granted inducement awards consisting of nonstatutory stock options"
Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.
nonstatutory stock optionsfinancial
"granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
exercise pricefinancial
"Each stock option has an exercise price equal to $8.34 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares of common stock to six (6) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $8.34 per share, the closing price of the Company’s common stock on April 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KURA announce about inducement grants on April 1, 2026?
Kura granted nonstatutory stock options for 153,750 shares to six new employees. According to the company, the awards were made under the 2023 Inducement Option Plan and approved as inducement awards under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the KURA inducement stock options dated April 1, 2026?
The exercise price is $8.34 per share, equal to the closing price on April 1, 2026. According to the company, each option’s price matches that closing price and is subject to the option agreement and plan terms.
How do the KURA inducement options vest for the six new employees?
The options vest over four years: 25% at one year, then monthly over the following 36 months. According to the company, vesting is contingent on the new employees’ continued service through applicable vesting dates.
Under which plan were the KURA inducement awards granted and why?
The awards were granted under the 2023 Inducement Option Plan, as amended, as inducement material to employment. According to the company, the Compensation Committee approved them in accordance with Nasdaq Listing Rule 5635(c)(4).
How many employees received KURA inducement stock options and what is the total share amount?
Six new employees received inducement awards totaling 153,750 shares of common stock. According to the company, the grants were nonstatutory stock options approved by the Compensation Committee on April 1, 2026.
